Investigation Report on Recombinant Human Coagulation Factor VIII in China, 2018-2022
DESCRIPTION
There are more than 400,000 people with hemophilia in the world, Chinese surpassing 100,000. The registered hemophilia patients in China are less than 20,000, because most patients give up treatment due to the expensive medical expenses. Those who lack coagulation factor VIII account for 80% to 85% of the hemophilia A patients. Currently, there is no cure for hemophilia, treatment for which on the market are all alternatives. Coagulation factors are the main drugs.
In 1992, Baxter (Baxalta) publicized the first recombinant coagulation factor VIII. Because it has the same effects as natural coagulation factors without risks of blood-borne virus contamination, it is very popular in the market. The developed countries master mature technologies of recombinant coagulation factors. For example, recombinant coagulation factor VIII now has experienced four rounds of upgradation. The main manufacturers are Bayer, Baxalta, Wyeth, etc. By Jun. 2018, no domestic recombinant coagulation factor VIII has been launched. In May 2018, China's local biopharmaceutical company Beijing Tiantan Biological Products Co., Ltd. announced that its subsidiary Chengdu Rongsheng Pharmaceutical Co., Ltd. had received Approval Document for Clinical Trials of recombinant human coagulation factor VIII for injection issued by the CFDA.
Recombinant human coagulation factor VIII developed rapidly after entering China. Its annual sales increased from less than CNY 6 million in 2009 to CNY 300 million in 2017, and the CAGR reached 65.2% from 2009 to 2017. Currently, recombinant human coagulation factor VIII sold on the Chinese market is all imported from Bayer, Baxalta and Wyeth. Bayer secures the highest market share, which was close to 68% in 2017.
CRI forecasts that with the development of China's economy, patients with hemophilia are more able to pay medical expenses. It is expected that the market scale of recombinant human coagulation factor VIII in China will continue to increase from 2018 to 2022. After 2022, there is possibility that Chinese companies may launch recombinant human coagulation factor VIII.
TOPICS COVERED
There are more than 400,000 people with hemophilia in the world, Chinese surpassing 100,000. The registered hemophilia patients in China are less than 20,000, because most patients give up treatment due to the expensive medical expenses. Those who lack coagulation factor VIII account for 80% to 85% of the hemophilia A patients. Currently, there is no cure for hemophilia, treatment for which on the market are all alternatives. Coagulation factors are the main drugs.
In 1992, Baxter (Baxalta) publicized the first recombinant coagulation factor VIII. Because it has the same effects as natural coagulation factors without risks of blood-borne virus contamination, it is very popular in the market. The developed countries master mature technologies of recombinant coagulation factors. For example, recombinant coagulation factor VIII now has experienced four rounds of upgradation. The main manufacturers are Bayer, Baxalta, Wyeth, etc. By Jun. 2018, no domestic recombinant coagulation factor VIII has been launched. In May 2018, China's local biopharmaceutical company Beijing Tiantan Biological Products Co., Ltd. announced that its subsidiary Chengdu Rongsheng Pharmaceutical Co., Ltd. had received Approval Document for Clinical Trials of recombinant human coagulation factor VIII for injection issued by the CFDA.
Recombinant human coagulation factor VIII developed rapidly after entering China. Its annual sales increased from less than CNY 6 million in 2009 to CNY 300 million in 2017, and the CAGR reached 65.2% from 2009 to 2017. Currently, recombinant human coagulation factor VIII sold on the Chinese market is all imported from Bayer, Baxalta and Wyeth. Bayer secures the highest market share, which was close to 68% in 2017.
CRI forecasts that with the development of China's economy, patients with hemophilia are more able to pay medical expenses. It is expected that the market scale of recombinant human coagulation factor VIII in China will continue to increase from 2018 to 2022. After 2022, there is possibility that Chinese companies may launch recombinant human coagulation factor VIII.
TOPICS COVERED
- Development of Recombinant Human Coagulation Factor VIII in China
- Sales of Recombinant Human Coagulation Factor VIII in China
- Sale price of Recombinant Human Coagulation Factor VIII in the Chinese market
- Manufacturers of Recombinant Human Coagulation Factor VIII in the Chinese market
- Research progress of Chinese companies on Recombinant Human Coagulation Factor VIII
- Chinese market prospects on Recombinant Human Coagulation Factor VIII from 2018 to 2022
1 RELEVANT CONCEPTS OF RECOMBINANT HUMAN COAGULATION FACTOR VIII
1.1 Indication
1.2 Development in China
2 CHINESE MARKET OVERVIEW OF RECOMBINANT HUMAN COAGULATION FACTOR VIII
2.1 Patents and Government Approval on Drugs
2.2 Major Manufacturers
3 SALES OF RECOMBINANT HUMAN COAGULATION FACTOR VIII IN CHINA, 2013-2017
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value in Key Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume in Key Regions
3.3 Sales of Different Dosage Forms
4 MARKET SHARE OF MAJOR MANUFACTURERS OF RECOMBINANT HUMAN COAGULATION FACTOR VIII IN CHINA, 2013-2017
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 MAJOR MANUFACTURERS AND REFERENCE SALE PRICE OF RECOMBINANT HUMAN COAGULATION FACTOR VIII IN CHINESE MARKET, 2017-2018
5.1 Bayer
5.1.1 Enterprise Profile
5.1.2 Sales of Bayer's Recombinant Human Coagulation Factor VIII
5.1.3 Average Sale Price of Bayer's Recombinant Human Coagulation Factor VIII in Parts of China
5.2 Baxalta
5.3 Wyeth
6 MARKET PROSPECTS OF RECOMBINANT HUMAN COAGULATION FACTOR VIII, 2018-2022
6.1 Forecast on Factors Influencing Development
6.2 Forecast on Market Size
6.3 Forecast on Development Trend
PART OF CHARTS
Chart Patents of Recombinant Human Coagulation Factor VIII in China
Chart Sales of Recombinant Human Coagulation Factor VIII in China
Chart Sales Value of Recombinant Human Coagulation Factor VIII in China, 2013-2017
Chart Sales Value of Recombinant Human Coagulation Factor VIII in Parts of China, 2013-2017
Chart Sales Volume of Recombinant Human Coagulation Factor VIII in China, 2013-2017
Chart Sales Volume of Recombinant Human Coagulation Factor VIII in Parts of China, 2013-2017
Chart Sales Value and Market Share of Bayer's Recombinant Human Coagulation Factor VIII in China, 2013-2017
Chart Sales Value and Market Share of Baxalta's Recombinant Human Coagulation Factor VIII in China, 2013-2017
Chart Sales Value and Market Share of Wyeth's Recombinant Human Coagulation Factor VIII in China, 2013-2017
Chart Sale Price of Bayer's Recombinant Human Coagulation Factor VIII in Some Chinese Cities, 2017-2018
Chart Sale Price of Baxalta's Recombinant Human Coagulation Factor VIII in Some Chinese Cities, 2017-2018
Chart Forecast on Sale Price of Recombinant Human Coagulation Factor VIII in China, 2018-2022
COMPANIES MENTIONED
1 Bayer
2 Baxalta
3 Wyeth
1.1 Indication
1.2 Development in China
2 CHINESE MARKET OVERVIEW OF RECOMBINANT HUMAN COAGULATION FACTOR VIII
2.1 Patents and Government Approval on Drugs
2.2 Major Manufacturers
3 SALES OF RECOMBINANT HUMAN COAGULATION FACTOR VIII IN CHINA, 2013-2017
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value in Key Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume in Key Regions
3.3 Sales of Different Dosage Forms
4 MARKET SHARE OF MAJOR MANUFACTURERS OF RECOMBINANT HUMAN COAGULATION FACTOR VIII IN CHINA, 2013-2017
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 MAJOR MANUFACTURERS AND REFERENCE SALE PRICE OF RECOMBINANT HUMAN COAGULATION FACTOR VIII IN CHINESE MARKET, 2017-2018
5.1 Bayer
5.1.1 Enterprise Profile
5.1.2 Sales of Bayer's Recombinant Human Coagulation Factor VIII
5.1.3 Average Sale Price of Bayer's Recombinant Human Coagulation Factor VIII in Parts of China
5.2 Baxalta
5.3 Wyeth
6 MARKET PROSPECTS OF RECOMBINANT HUMAN COAGULATION FACTOR VIII, 2018-2022
6.1 Forecast on Factors Influencing Development
6.2 Forecast on Market Size
6.3 Forecast on Development Trend
PART OF CHARTS
Chart Patents of Recombinant Human Coagulation Factor VIII in China
Chart Sales of Recombinant Human Coagulation Factor VIII in China
Chart Sales Value of Recombinant Human Coagulation Factor VIII in China, 2013-2017
Chart Sales Value of Recombinant Human Coagulation Factor VIII in Parts of China, 2013-2017
Chart Sales Volume of Recombinant Human Coagulation Factor VIII in China, 2013-2017
Chart Sales Volume of Recombinant Human Coagulation Factor VIII in Parts of China, 2013-2017
Chart Sales Value and Market Share of Bayer's Recombinant Human Coagulation Factor VIII in China, 2013-2017
Chart Sales Value and Market Share of Baxalta's Recombinant Human Coagulation Factor VIII in China, 2013-2017
Chart Sales Value and Market Share of Wyeth's Recombinant Human Coagulation Factor VIII in China, 2013-2017
Chart Sale Price of Bayer's Recombinant Human Coagulation Factor VIII in Some Chinese Cities, 2017-2018
Chart Sale Price of Baxalta's Recombinant Human Coagulation Factor VIII in Some Chinese Cities, 2017-2018
Chart Forecast on Sale Price of Recombinant Human Coagulation Factor VIII in China, 2018-2022
COMPANIES MENTIONED
1 Bayer
2 Baxalta
3 Wyeth
